Document:

Exhibit

Exhibit 4.4

HOLLYFRONTIER CORPORATION
2020 LONG TERM INCENTIVE PLAN (THE “PLAN”)
SUB-PLAN FOR U.K. EMPLOYEES (THE “SUB-PLAN”)
This Sub-Plan is a sub-plan of the Plan and has been created and approved in accordance with the provisions of Section 3(e)(iv) of the Plan.  Terms defined in the Plan shall have the same meanings in this Sub-Plan unless otherwise defined in this Sub-Plan.
SECTION 1    Definitions.  As used in this Sub-Plan and/or any Award Agreement under this Sub-Plan, the following terms shall have the meanings set forth below.
(a)    “Employer’s NICs” means the amount of secondary Class 1 national insurance contributions payable in respect of any Award.
(b)    “FPO” means the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 of the United Kingdom (as may be amended from time to time).
(c)    “FSMA” means the Financial Services and Markets Act 2000 of the United Kingdom (as may be amended from time to time).
(d)    “Group” has the meaning given to that term under FSMA.
(e)    “U.K. Employee” means an employee or former employee of the Company or of any Affiliate (provided that such Affiliate is a member of the Company’s Group) who is resident in the United Kingdom.
SECTION 2    Purpose.
(a)    The purpose of this Sub-Plan is primarily to establish a sub-plan under the auspices of the Plan that will apply to Awards to be made to U.K. Employees.  As a result:
(i)    All Awards to U.K. Employees shall be made under this Sub-Plan; 
(ii)    No Awards shall be made under this Sub-Plan to any person other than a U.K. Employee, and this Sub-Plan shall not apply to any Awards made under the Plan to any such other person; and
(iii)    Section 5(a) of the Plan shall be deemed amended accordingly insofar as it applies to this Sub-Plan.
(b)    The provisions of the Sub-Plan vary from those applicable under the Plan so as to 
(i)    enable the Sub-Plan (and any Awards made or proposed to be made under the Sub-Plan, and communications concerning those Awards) to take advantage of certain exemptions available in the United Kingdom from certain prohibitions and restrictions which 

might otherwise apply to such grants and communications in the United Kingdom under the regulatory regime established under FSMA; and 
(ii)    take account of United Kingdom tax treatment of the Awards.
(c)    No Award shall be granted under this Sub-Plan unless such Award relates to a type of investment set out or referred to in Article 60(1) of the FPO.  Section 6 of the Plan shall be deemed amended accordingly insofar as it applies to this Sub-Plan.
SECTION 3    Interaction with the Plan.
(a)    This Sub-Plan should be read in conjunction with the Plan and is subject to the terms and conditions of the Plan except to the extent that the terms and conditions of the Plan differ from or conflict with the terms set out in this Sub-Plan, in which event, the terms set out in this Sub-Plan shall prevail.
(b)    Subject to the other provisions of this Sub-Plan, the provisions of the Plan will apply to this Sub-Plan as if references therein to the Plan were references to this Sub-Plan.
SECTION 4    Taxes
(a)    Section 9(a) of the Plan shall not apply to this Sub-Plan.  
(b)    All Awards under this Sub-Plan shall be subject to applicable United Kingdom taxes and national insurance contributions.  As a condition to the issuance, vesting, exercise or settlement of any Award, the Participant shall be required to pay to the Company or any relevant Affiliate that employs the Participant, or make other arrangements satisfactory to the Company or the relevant Affiliate to provide for the payment of, any national, federal, state or local or other taxes, social security and employee’s United Kingdom national insurance contributions (“Employment Taxes”) that the Company or the relevant Affiliate is required to withhold, or in respect of which the Company or the relevant Affiliate is required to account to any tax authority including HM Revenue & Customs (“HMRC”), with respect to any income or gains arising or deemed to arise to the Participant in connection with any Award (including for the avoidance of doubt in connection with the exercise of any Option and/or vesting, holding or disposal of any Stock received pursuant to any Award).  The Committee, in its discretion, may permit the satisfaction of such Employment Taxes by having Stock withheld from delivery with respect to any Award up to a value that does not exceed the relevant required amount of Employment Taxes, and the Committee, in its discretion, may take such other action as the Committee may deem advisable to enable the Company, its Affiliates and Participants to satisfy the obligation for such Employment Taxes relating to any Award in such amounts may be determined by the Committee.  The Committee shall determine, in its sole discretion, the form of payment acceptable to satisfy such Employment Tax obligation, including the delivery of cash or cash equivalents, Stock (including through delivery of previously owned shares, net settlement, a broker-assisted sale, or other cashless withholding or reduction of the amount of shares otherwise issuable or delivered pursuant to the Award; provided that if the Employment Tax obligation is satisfied by net settlement, for tax purposes, the Participant is deemed to have been issued the 

full number of shares of Stock subject to the Award, notwithstanding that a number of shares of Stock are withheld solely for purposes of satisfying the Employment Tax obligation), other property, or any other legal consideration the Committee deems appropriate.  Any determination made by the Committee to allow a Participant who is subject to Rule 16b-3 to pay such taxes or other amounts with shares of Stock through net settlement or previously owned shares shall be approved by either a committee made up of solely two or more Qualified Members or the full Board.  If such obligations for taxes or other amounts are satisfied through net settlement or previously owned shares, the maximum number of shares of Stock that may be so withheld or surrendered shall be the number of shares of Stock that have an aggregate Fair Market Value on the date of withholding or surrender equal to the aggregate amount of such liabilities for taxes and other amounts determined based on the greatest withholding rates for taxes and other amounts that may be utilized without creating adverse accounting treatment for the Company with respect to such Award, as determined by the Committee.  The Company or the relevant Affiliate is authorised to withhold from (i) any Award made, (ii) any payment relating to an Award under this Sub-Plan, including from a distribution of Stock, and (iii) any payroll or other payment to a Participant, the amount of required Employment Taxes due or potentially payable in connection with any transaction involving an Award under this Sub-Plan to the maximum extent permitted by law and regulation.  To the extent any amount is withheld by the Company in accordance with this section, such amount shall either be remitted to the relevant Affiliate on behalf of the Participant, or deemed to have been so remitted where the amount is paid to a relevant tax authority on behalf of such relevant Affiliate. 
(c)    The Participant may be required as a condition precedent to acquiring any Stock or exercising any Option to enter into a joint election under Section 431(1) of the United Kingdom Income Tax (Earnings and Pensions) Act 2003 for the full disapplication of Chapter 2 of Part 7 of that Act.  
(d)    In accepting any relevant Award, the Participant shall, if so required by the Company and to the extent lawful, agree with and undertake to the Company and any relevant Affiliate that is a “secondary contributor” in respect of Class I national insurance contributions payable in respect of the Award (or any Stock award in connection therewith) that the Company or relevant Affiliate may recover from the Participant the whole or part of any Employer’s NICs; and the Participant shall either (A) (if so required the Company) join with the Company or relevant Affiliate in making an election (in such terms and such form and subject to such approval by HMRC as provided in paragraph 3B of Schedule 1 to the Social Security Contributions and Benefits Act 1992) for the whole or part of any liability of the Company or relevant Affiliate for Employer’s NICs to be transferred to the Participant, or (B) enter into a joint agreement with the Company or relevant Affiliate at the time of the Award for the reimbursement by the Participant to the Company or relevant Affiliate for such Employer’s NICs. 

SECTION 5    General.
(a)    The Sub-Plan, and any Awards granted hereunder, shall be governed, construed and administered in accordance with the laws of the State of Texas, without reference to its conflict of laws provisions.
(b)    The terms and conditions provided in this Sub-Plan are severable and if (despite the provisions of Section 5(a) of this Sub-Plan) any one or more provisions (or the effect of any such provision) are determined to be illegal or otherwise unenforceable under any applicable law, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.EX-10.30

 Exhibit 10.30 

RESEARCH COLLABORATION AGREEMENT 
 This
Agreement is between the National Center for Advancing Translational Sciences (“NCATS”), which is a component of the National Institutes of Health (“NIH”), an agency of the U.S. Department of Health and Human Services, having
offices located at 9800 Medical Center Drive, Rockville, MD 20850, and Acer Therapeutics Inc., (“Collaborator”), having a principal place of business at One Gateway Center, 300 Washington Street, Suite 351, Newton, MA 02458 (collectively,
the “Parties”). This Agreement is neither a funding agreement as defined in 35 U.S.C. § 201(b) nor a cooperative research and development agreement authorized under the Federal Technology Transfer Act of 1986, as amended, 15 U.S.C.
§§ 3710a et seq., and Executive Order 12591 of April 10, 1987. NCATS enters into this Agreement pursuant to the authority of the Public Health Services Act of 1944, as amended (42 U.S.C. § 241). 

BACKGROUND 
  

	 	1.	 NCATS and Collaborator want to collaborate on a research project; and 

 

	 	2.	 NCATS and Collaborator want to transfer between the laboratories of their investigators, during the term of
this Agreement, proprietary research materials required to conduct the research project. 

  

	 	3.	 Acer Therapeutics is actively pursuing the development of this opportunity, and may benefit from specific
experience about emetine held by NCATS and capabilities for development that exist within the intramural research program. 

TERMS AND CONDITIONS 

Article 1 DEFINITIONS 
  

	1.1	 “Confidential Information” includes scientific, business, or financial information
pertaining to the Research Project (defined below) that is designated as confidential by Provider (defined below). Confidential Information does not include information that: (i) is in the public domain other than as a result of a disclosure by
Recipient (defined below) or any of Recipient’s representatives in violation of this Agreement; (ii) was in the possession of Recipient before disclosure by the Provider; (iii) is acquired by Recipient from a third party having no
obligation of confidentiality to Provider; (iv) is hereafter independently developed by Recipient, without reference to Confidential Information received from Provider; or (v) Provider expressly authorizes Recipient to disclose.

  

	1.2	 “Invention” means any invention or discovery that is or may be patentable or
protectable under applicable laws. 

  

	1.3	 “Investigator” means the principal researcher designated by a Party to direct the
Research Project. 

  

	1.4	 “Material” means Original Material such as chemical compounds, peptides or natural
products, and any material created by Recipient that constitutes an unmodified functional subunit of or product derived from Original Material. 

  

	1.5	 “Original Material” means a material provided by one of the Parties and used in the
Research Project. 

  

	1.6	 “Provider” means the Party that provides Original Material or discloses Confidential
Information to the other Party under this Agreement. 

  

			
	 Research Collaboration Agreement
 NCATS / Acer
Therapeutics
 Southall / Schelling
	  	Page 1 of 9

	1.7	 “Recipient” means the Party that receives Original Material or Confidential Information
from the other Party under this Agreement. 

  

	1.8	 “Research Project” means the collaborative research described in Appendix A.

  

	1.9	 “Data” refers to any information generated throughout the course of the execution of the
Research Project. 

 Article 2 COLLABORATIVE RESEARCH 
  

	2.1	 NCATS and Collaborator agree to collaborate on the Research Project. The Investigator for NCATS will be
Dr. Noel Southall, and additional Investigators for NCATS will be Drs. Juan Marugan, Mark Henderson. The Investigator for Collaborator will be Chris Schelling, CEO and Founder of Collaborator. 

 

	2.2	 Nothing in this Agreement will be construed to limit the freedom of either Party from engaging in
similar research with other parties, providing the research does not create a conflict with the Parties’ obligations under this Agreement, especially with regard to Article 3. 

 

	2.3	 The Parties recognize that the Research Project describes the collaborative research to be conducted
under this Agreement and that the goals set forth in Appendix A are good faith guidelines. If events occur that require substantial modification of the Research Project, the Parties may amend Appendix A according to Paragraph 6.2.1 of this
Agreement. 

 Article 3 CONFIDENTIALITY; PUBLICATIONS 
  

	3.1	 Confidential Information 

 

	 	3.1.1	 Either Party may disclose or receive Confidential Information under this Agreement. 

 

	 	3.1.2	 All Confidential Information exchanged between the Parties must conspicuously bear the words “Confidential
Information” or “Confidential.” Confidential Information exchanged orally or through observation must be reduced to writing and marked “Confidential Information” or “Confidential” within 30 days after disclosure to
be considered Confidential Information. 

  

	 	3.1.3	 The obligation to maintain the confidentiality of Confidential Information will expire at the earlier of the
date when the information is no longer Confidential Information as defined in Paragraph 1.1 or three (3) years after the expiration or termination date of this agreement. 

 

	 	3.1.4	 Recipient may disclose Confidential Information to its employees, consultants, or contractors to whom it is
necessary to disclose this information for the purpose of the Research Project; Recipient may make these disclosures only under terms at least as restrictive as those specified in this Agreement. Recipient agrees that disclosure of Confidential
Information may not be made to any party not listed herein unless Provider grants prior written approval to Recipient. 

  

	 	3.1.5	 Recipient may disclose Provider’s Confidential Information if required to do so by law, regulation, or
court order. If Recipient, or anyone to whom it discloses Confidential Information in accordance with Article 3, becomes legally required to disclose any Confidential Information, Recipient will provide timely notice to Provider and, to the extent
practicable, consult with Provider prior to any disclosure. 

  

	 	3.1.6	 Either Party may disclose the Abstract of the Research Project (in Appendix A) to the public.

  

			
	 Research Collaboration Agreement
 NCATS / Acer
Therapeutics
 Southall / Schelling
	  	Page 2 of 9

	3.2	 Publications; Press Releases 

 

	 	3.2.1	 Publications 

  

	 	3.2.1.1	 In addition to the specific goals of the Research Project, the Parties view dissemination of research findings,
both by publication and oral presentation, as an essential objective of the Research Project. Authorship will be decided according to commonly accepted conventions for scientific publications. 

 

	 	3.2.1.2	 The Parties are encouraged to make publicly available the results of the Research Project. Before either Party
submits a paper or abstract for publication or otherwise intends to publicly disclose information about any Invention made in the course of the Research Project, the other Party will have 30 days to review proposed manuscripts and 3 business days to
review proposed abstracts to assure that its Confidential Information is protected. Either Party may request in writing that the proposed publication or other disclosure be delayed for up to 30 additional days as necessary to file a patent
application. 

  

	 	3.2.2	 Press Releases 

Collaborator-issued press releases that reference or rely upon the work of NCATS under this Agreement will be made available to NCATS for
review and comment at least 3 business days prior to publication. 
 Article 4 INVENTIONS; DATA 

 

	4.1	 Inventions 

  

	 	4.1.1	 The Parties acknowledge the possibility that Inventions may be made in the course of the Research Project.
Inventorship of those Inventions will be determined in accordance with applicable U.S. laws and regulations. The term made, as used in reference to any invention, means the conception or first actual reduction to practice of such invention.

  

	 	4.1.2	 Inventions made in the course of the Research Project will be owned by the Party employing the inventor or
inventors. Inventions that are invented jointly by employees of both Parties will be owned jointly. 

  

	 	4.1.3	 Each Party will report to the other Party, in writing, all Inventions made during the Research Project no later
than 3 months from the time the invention is disclosed to a Party by its Investigator. The reports will be written in sufficient detail to determine inventorship and will be treated as Confidential Information in accordance with Article 3. The
Parties will confer with each other regarding a patent filing strategy for jointly made Inventions. If either Party files a patent application on a jointly made Invention, then the filing Party will include a statement in the patent application that
clearly identifies the Parties and states that the Invention was made jointly under this Agreement. 

  

	4.2	 Data 

Each Party will disclose to the other Party a summary of all Data generated under this Agreement. Subject to the restrictions in Article 3,
both Parties will have free access to and use of any Data generated under this Agreement. Collaborator and NCATS will use reasonable efforts to keep Data confidential until published or until corresponding patent applications are filed. 

  

			
	 Research Collaboration Agreement
 NCATS / Acer
Therapeutics
 Southall / Schelling
	  	Page 3 of 9

 Article 5 THE TRANSFER AND USE OF MATERIAL 

 

	5.1	 Mechanics of Transfer 

Either Party may provide or receive Original Material under this Agreement. If either Party transfers to the other Party a material not listed
in Appendix A, the Parties will amend this Agreement to include the additional material. 
  

	5.2	 Transfer of Personally Identifiable Information (PII) 

At no time throughout the course of the Research Project will PII be exchanged. Further to this, no key or code which links the original donor
to any materials will be provided. 
  

	5.3	 Conditions of Use 

 

	 	5.3.1	 RECIPIENT WILL NOT USE MATERIAL IN RESEARCH INVOLVING HUMAN SUBJECTS. 

 

	 	5.3.2	 Recipient’s Investigator will use Material solely in connection with the Research Project in the
Investigator’s laboratory (including any Contract Manufacturing Organization or similar outsourced service provider who will agree to all of the terms and conditions of this agreement). If Recipient wants to use Material for commercial
purposes, Recipient agrees to first obtain the appropriate commercial use or commercialization license from Provider. 

  

	 	5.3.3	 Recipient agrees that Recipient’s Investigator will retain control over Material and further agrees that
Recipient’s Investigator will not transfer Material to people not under the Investigator’s direct supervision without advance written approval of Provider. 

 

	 	5.3.4	 Recipient will use Material in compliance with all applicable laws, regulations and policies.

  

	 	5.3.5	 Provider reserves the right to distribute its Material to others and to use its Material for its own purposes.

  

	 	5.3.6	 Upon termination of this Agreement, Recipient agrees that Recipient’s Investigator will return any and all
remaining Original Material unless Provider gives Recipient’s Investigator directions for disposing of Original Material by another means. 

  

	 	5.3.7	 Nothing in this Agreement will be construed as conferring on Recipient any implied license to Material, or
option to license Material, any technology, or any patent or patent application owned by Provider and will not create any obligation, by implication or otherwise, of either Party to enter into any further agreement with the other Party.

 Article 6 TERMINATION AND GOVERNANCE 
  

	6.1	 Effective Date 

This Agreement will be effective on the date of the last authorized signature below. 

 

	6.2	 Term and Termination 

 

	 	6.2.1.	 The Parties agree that this Agreement will be effective for 1 year from the date of the last authorized
signature below and may be extended as mutually agreed by the Parties in a written amendment to this Agreement. 

  

	 	6.2.2	 This Agreement will terminate immediately upon the mutual agreement of the Parties in writing.

  

			
	 Research Collaboration Agreement
 NCATS / Acer
Therapeutics
 Southall / Schelling
	  	Page 4 of 9

	 	6.2.3	 This Agreement will terminate in 30 days after either Party receives written notice of the other Party’s
desire to terminate this Agreement. 

  

	6.3	 Representations, Warranties, and Liability 

 

	 	6.3.1	 Material is understood to be experimental in nature and may have hazardous properties. ORIGINAL MATERIAL IS
BEING SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Provider makes no representations that the use of Material will not infringe any patent or other
proprietary rights of third parties. 

  

	 	6.3.2	 No indemnification for any loss, claim, damage, or liability is intended or provided by either Party under this
Agreement. Each Party will be liable for any loss, claim, damage, or liability that the Party incurs as a result of its activities under this Agreement, except that NCATS, as an agency of the U.S. Government, assumes liability only to the extent
provided under the Federal Tort Claims Act, 28 U.S.C. §§ 2671 et seq. 

  

	6.4	 Final Reports 

The Parties will exchange final reports of their results within four (4) months after the expiration or termination of this Agreement or
within an agreed upon time by all parties. These reports will set forth the technical progress made; any publications arising from the research; and the existence of invention disclosures of potential Inventions and/or any corresponding patent
applications. 
  

	6.5	 Assignment 

Neither this Agreement nor any rights or obligations of either Party hereunder may be assigned or otherwise transferred by either Party without
the prior written consent of the other Party. This Agreement will be binding upon the Parties and their respective successors and permitted assigns. 
  

	6.6	 Non-endorsement 

By entering into this Agreement, NCATS does not directly or indirectly endorse any product or service that is or will be provided, whether
directly or indirectly related to this Agreement, by Collaborator, its successors, permitted assigns, or licensees. Collaborator will not in any way state or imply that this Agreement is an endorsement of any such product or service by the U.S.
Government or any of its organizational units or employees. 
  

	6.7	 Survivability 

Articles 3, 4, 6.3, 6.5, 6.6 and 6.8 will survive expiration or earlier termination of this Agreement. 

 

	6.8	 Severability 

The illegality or invalidity of any provisions of this Agreement will not impair, affect, or invalidate the other provisions of this Agreement.

  

	6.9	 Governing Law 

The construction, validity, performance, and effect of this Agreement will be governed by federal law as applied by the federal courts in the
District of Columbia. Federal law and regulations will preempt any conflicting or inconsistent provisions in this Agreement. 
  

	6.10	 Entire Agreement 

This Agreement, together with all appendices, constitutes the entire agreement between the Parties and supersedes any prior or contemporaneous
oral or written agreements or communications between them with respect to the subject matter hereof. This Agreement may be amended only by written instrument signed by authorized representatives of NCATS and Collaborator. 

  

			
	 Research Collaboration Agreement
 NCATS / Acer
Therapeutics
 Southall / Schelling
	  	Page 5 of 9

	6.11	 Notices 

All notices pertaining to or required by this Agreement shall be in writing, shall be signed by an authorized representative and shall be
delivered to the addresses indicated on the signature page for each Party by email. 
  

	6.12	 Execution 

For the convenience of the Parties, this Agreement may be executed and transmitted by facsimile or email in Portable Document Format (PDF), and
in counterparts, each of which shall be deemed to be an original, and each of which taken together, shall constitute one agreement binding on all the Parties. 

SIGNATURES BEGIN ON THE NEXT PAGE 

  

			
	 Research Collaboration Agreement
 NCATS / Acer
Therapeutics
 Southall / Schelling
	  	Page 6 of 9

 FOR NCATS: 
  

							
	/s/ Lili M. Portilla Weingarten-S	 		 		 	3-26-20
	Lili Portilla, Director of Strategic Alliances	 		 		 	Date

 Mailing Address for Notices: 

ATTN: COLLABORATION AGREEMENT 
 NCATS Office of Strategic
Alliances 
 9800 Medical Center Drive, Room B311 
 Rockville,
MD 20852 
 Email: portilll@mail.nih.gov; ami.gadhia@nih.gov 

With email copy to: southalln@mail.nih.gov 

Acknowledgment by NCATS’s Investigator: 
  

							
	/s/ Noel Southall	 		 		 	3-26-20
	 Noel Southall, Ph.D., DPI Informatics Leader
	 		 		 	Date

 FOR ACER THERAPEUTICS INC.: 
  

							
	/s/ Christopher Schelling	 		 		 	3/25/2020
	Christopher Schelling	 		 		 	Date

 CEO and Founder
                     Acer legal review:

 

                   COFO:

 
 Mailing Address for Notices: 

Acer Therapeutics Inc. 
 One Gateway Center 

300 Washington Street, Suite 251 
 Newton, MA 02458 

Tel: (844) 902-6100    Fax: n/a 

Email: cschelling@acertx.com 
 With email copy to:
djoseph@acertx.com 
 Acknowledgment by COLLABORATOR’s Investigator: 
  

							
	/s/ Christopher Schelling	 		 		 	3/25/2020
	Christopher Schelling	 		 		 	Date

 Acer legal review:

 
 COFO:

 

  

			
	 Research Collaboration Agreement
 NCATS / Acer
Therapeutics
 Southall / Schelling
	  	Page 7 of 9

 APPENDIX A 

Research Project 
  

	I.	 Abstract of the Research Project – for Public Release 

EITHER PARTY MAY, WITHOUT FURTHER CONSULTATION
OR PERMISSION, RELEASE THIS ABSTRACT TO THE PUBLIC. 

Acer Therapeutics Inc. and the National Center for Advancing Translational Science (NCATS) are working together to speed the development of emetine for the
treatment of SARS-CoV-2 infection. The goal of Acer Therapeutics is to develop therapies for patients with serious and life-threatening disease, and bring significant
expertise in the clinical development, manufacturing and regulatory interactions required for product development. The current pandemic has created unprecedented challenges for the world. NCATS scientists identified emetine as a potential
therapeutic intervention and are working with Acer Therapeutics to help bring this intervention to patients in need. 
  

	II.	 Goal(s) of Project 

Accelerating the clinical development of emetine hydrochloride for treatment of
SARS-CoV-2 infection, including: 
 Contributing to a review of the existing
clinical experience with emetine for regulatory submissions Sharing materials, expertise and data that speed the generation of non-clinical safety and efficacy data to support clinical development goals 

Providing drug material and conducting a clinical proof of concept trial in patients with
SARS-CoV-2 infection. 
  

	III.	 Background 

Emetine was previously identified as a broad-acting antiviral and identified as by NCATS. After initially considering CMV, SARS-CoV-2 emerged recently as the best opportunity for further clinical development. 
 Acer Therapeutics is
actively pursuing the development of this opportunity, and may benefit from specific experience about emetine held by NCATS and capabilities for development that exist within the intramural research program. 

 

	IV.	 Respective Contributions of the Parties 

Acer Therapeutics has defined a target product profile for this clinical opportunity and are generating data packages for submission to FDA under an Emergency
Use Application (EUA) to support human clinical testing. NCATS has completed a literature review of clinical experience with emetine use, as well as important artifacts including previous drug product labels, and a drug master file that it intends
to share. NCATS also has access to considerable physical material (50g) of emetine to support further nonclinical safety and efficacy studies as needed. 

  

			
	 Research Collaboration Agreement
 NCATS / Acer
Therapeutics
 Southall / Schelling
	  	Page 8 of 9

	V.	 Material Contributed by NCATS 

NCATS has completed a literature review of clinical experience with emetine use, as well as important artifacts including previous drug product labels, a drug
master file that it intends to share. NCATS also has access to considerable physical material (50g) of emetine to support further nonclinical safety and efficacy studies as needed. Finally, NCATS has development expertise available in-house and through collaboration and contract that may help fill gaps in the current Acer Therapeutics development package. 
  

	VI.	 Material Contributed by Collaborator 

Acer Therapeutics has defined a target product profile for this clinical opportunity and will share details on aspects of its clinical development program as
needed on identified gaps to facilitate the urgent development of this therapy. 
  

	VII.	 Experimental Plan 

Acer Therapeutics and NCATS will coordinate activities by frequent email contact and through regular phone calls on data sharing, problem solving, materials
sharing and data generation relevant to emetine regulatory submissions. 

  

			
	 Research Collaboration Agreement
 NCATS / Acer
Therapeutics
 Southall / Schelling
	  	Page 9 of 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]